It has been shown miR-218 could inhibit cancer cell migration and invasion by targeting focal adhesion pathway [23], impair tumor growth and increase chemo-sensitivity to cisplatin through regulating the AKT-mTOR signaling pathway [24] and suppress progression through downregulation of survivin and the SLIT2-ROBO1 pathway [25]. The gene discussed is BIRC5; the disease is neoplasm.